Back To School: Catch Up On Our Executive Interviews
This article was originally published in The Pink Sheet Daily
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
You may also be interested in...
Known as a specialty pharma focused on acquiring abandoned late-stage programs from other companies, TMC now is trying to differentiate itself in the industry with what Meanwell calls the company's "human strategy."
The Medicines Company gradually has revised its business model, moving into earlier-stage research, largely through the acquisition of two biotechs in the past year.
While fighting for a patent extension for its sales leader, the specialty pharma has adjusted its business model to include acquisitions and early-stage drug development.